Metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel (nab-P), bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancrea...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter Picozzi Vincent
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors P. Vincent1, R.L. Caio2, S. Vaibhav3, S. Diane3, O. Allyson4, P. Philip5, S. Wasif6, K. Aparna7, O. Michael8, S.L. Jack8, M. Victoria8
  • 1Virginia Mason, Seattle, Washington, USA, /
  • 2Gibbs Cancer Center and Research Institute, Spartanburg, South Carolina, USA, /
  • 3University of Michigan, Ann Arbor, Michigan, USA, /
  • 4Weill Cornell Medical College, New York, New York, USA, /
  • 5Karmanos Cancer Center, Detroit, Michigan, USA, /
  • 6Tufts Medical Center, Boston, Massachusetts, USA, /
  • 7Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA, /
  • 8Celgene Corporation, Summit, New Jersey, USA, /

Abstract

nab-P in combination with gemcitabine is a standard of care for the first-line treatment of MPC. Recently, multi-agent nab-P–based regimens, including nab-P + 5-FU + leucovorin and nab-P in combination with 5-FU + leucovorin + oxaliplatin (FOLFOX), have yielded promising results in this patient population. In a small, single-center study of patients with advanced pancreatic cancer, treatment with a 5-agent regimen of metronomic 5-FU, nab-P, bevacizumab, leucovorin, and oxaliplatin (FABLOx) resulted in a 50% partial response rate and a median overall survival (OS) of 17 months; however, the regimen's toxicity was substantial (Isacoff, ASCO 2012). This prospective, multicenter, phase 1/2 study will evaluate safety and efficacy of FABLOx in patients with MPC.